Dasatinib
- Generic Name
- Dasatinib
- Brand Names
- Sprycel
- Drug Type
- Small Molecule
- Chemical Formula
- C22H26ClN7O2S
- CAS Number
- 302962-49-8
- Unique Ingredient Identifier
- X78UG0A0RN
- Background
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeri...
- Indication
Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-posi...
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer
- First Posted Date
- 2006-10-09
- Last Posted Date
- 2013-04-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 94
- Registration Number
- NCT00385580
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸The Bunting Blaustein Cancer Research Building, Baltimore, Maryland, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug
- First Posted Date
- 2006-09-29
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 40
- Registration Number
- NCT00382668
- Locations
- 🇺🇸
University Of Miami, Miami, Florida, United States
🇺🇸New Orleans Center For Clinical Research, Knoxville, Tennessee, United States
🇺🇸Comprehensive Phase One, Miramar, Florida, United States
Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer
- First Posted Date
- 2006-09-04
- Last Posted Date
- 2011-04-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 92
- Registration Number
- NCT00371345
- Locations
- 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Ucsf-Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States
A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer
- First Posted Date
- 2006-09-04
- Last Posted Date
- 2011-03-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 55
- Registration Number
- NCT00371254
- Locations
- 🇺🇸
Dana-Farber Cancer Inst, Boston, Massachusetts, United States
🇺🇸University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States
🇪🇸Local Institution, Lleida, Spain
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2009-11-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 3
- Registration Number
- NCT00362466
- Locations
- 🇺🇸
Santee Hematology/Oncology, Sumter, South Carolina, United States
🇺🇸M.D. Anderson Cancer Center Orlando, Orlando, Florida, United States
🇺🇸Local Institution, Houston, Texas, United States
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL
- Conditions
- First Posted Date
- 2006-07-07
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00349518
- Locations
- 🇬🇧
Local Institution, Birmingham, West Midlands, United Kingdom
🇵🇱Local Instiution, Lodz, Poland
Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2013-01-08
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT00345826
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Study of Dasatinib (BMS-354825) in Patients With Solid Tumors
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2010-12-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 16
- Registration Number
- NCT00339144
- Locations
- 🇯🇵
Local Institution, Koto-Ku, Tokyo, Japan
Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 48
- Registration Number
- NCT00337454
- Locations
- 🇯🇵
Local Institution, Tokyo, Japan
Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 52
- Registration Number
- NCT00320190
- Locations
- 🇬🇧
Local Institution, Leeds, North Yorkshire, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.